UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                                 WASHINGTON D.C.

                                   FORM 10-QSB

      [X]   Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
            Exchange Act of 1934, For the Quarter Ended June 30, 2005

      [_]   Transitional Report Pursuant to Section 13 or 15(d) of the
            Securities Exchange Act of 1934

                          Commission File No. 000-28459

                      ADVANCED PLANT PHARMACEUTICALS, INC.

             (Exact name of Registrant as specified in its charter)



               Delaware                            59-2762023
        -------------------                    -------------------
   (State  of other jurisdiction       (I.R.S. Employer Identification Number)
of  incorporation  or  organization)


                 43 West 33rd Street, New York, New York 10001
                 ---------------------------------------------
                     Address of principal executive offices

        Registrant's telephone number, including area code: 212-695-3334

      Indicate by check mark whether the issuer (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities and Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
issuer was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                                 Yes [X] No [_]

      As of August 19, 2005, there were issued and outstanding 786,382,298,
shares of Common Stock, $.0007 par value per share.

      Transitional Small Business Disclosure Format

                  Yes [_] No [X]
<PAGE>

                      ADVANCED PLANT PHARMACEUTICALS, INC.

                                      INDEX
                                      -----






                                                                        PAGE
PART I.  FINANCIAL INFORMATION                                         NUMBER
         ---------------------                                       ----------

Item 1.  Condensed financial statements (unaudited)

         Condensed Balance sheet as of June 30, 2005                      3

         Condensed Statements of operations for the
           three and six months ended June 30, 2005
           and 2004                                                       4

         Condensed Statements of cash flows for the
           six months ended June 30, 2005 and 2004
                                                                          5

         Notes to the condensed financial statements                      7

Item 2.  Management's Discussion and Analysis of Financial
         Condition and Results of Operations                              11

Item 3.   Controls and Procedures                                         15

PART II.  OTHER INFORMATION                                               16
          ----------------

SIGNATURES                                                                17

<PAGE>

                                     PART I

ITEM 1. CONDENSED FINANCIAL STATEMENTS

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                           CONSOLIDATED BALANCE SHEETS


<TABLE>
<CAPTION>
                                                                    June 30,      December 31,
                                                                      2005            2004
                                                                 -------------   -------------
                                                                    Unaudited
                                     ASSETS

<S>                                                              <C>             <C>
CURRENT ASSETS
  Cash and cash equivalents                                      $      90,468   $       1,045
    Accounts receivable                                                                    306
   Inventory                                                             1,137
   Prepaid expenses                                                     13,200
                                                                 -------------   -------------

         Total Current Assets                                          104,805           1,351

OFFICE EQUIPMENT, net of accumulated depreciation of $2,383
    and $1,824, respectively                                             1,970           2,529
OTHER ASSETS
    Goodwill                                                            10,406          10,406

   Intangible assets, net of impairment losses                          24,599
   Due from related company                                              4,500
    Other assets                                                         7,144           7,144
                                                                 -------------   -------------

                                                                        46,649          17,550
                                                                 -------------   -------------
          Total Assets                                           $     153,424   $      21,430
                                                                 =============   =============
</TABLE>

                    LIABILITIES AND STOCKHOLDERS' DEFICIENCY
<TABLE>
<CAPTION>

<S>                                                              <C>             <C>
CURRENT LIABILITIES
   Bank overdraft                                                $      12,057   $       5,111
   Accounts payable                                                    162,774         167,108
   Accrued expenses                                                    701,446         568,983
   Accrued expenses - stockholders                                     989,212         901,246
    Due to distributor                                                 103,500         103,500
    Due to stockholder - asset acquisition                           1,315,000       1,315,000
   Loans payable - stockholders                                        258,446         228,796
   Deposits                                                            345,000
                                                                 -------------   -------------

         Total Current Liabilities                                   3,887,435       3,289,744

STOCKHOLDERS' DEFICIENCY
    Preferred stock, authorized 10,000,000 shares;
        $0.0007 par value; 5,000,000  and 2,500,000
        shares issued and outstanding at June 30,
        2005 and December 31, 2004, respectively                         3,500           1,750
   Common stock, authorized 880,000,000
        shares; $0.0007 par value; 797,157,996 and
        748,157,996 shares issued and outstanding at June 30,
        2005 and December 31, 2004, respectively                       558,011         523,711
   Additional paid-in capital                                       14,680,376      14,540,226
   Accumulated deficit                                             (18,975,898)    (18,334,001)
                                                                 -------------   -------------
   Total Stockholders' Deficiency                                   (3,734,011)     (3,268,314)
                                                                 -------------   -------------
          Total Liabilities and Stockholders' Deficiency         $     153,424   $      21,430
                                                                 =============   =============
</TABLE>


                 See accompanying notes to financial statements.

<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)


<TABLE>
<CAPTION>
                                           For the Three Months Ended          For the Six Months Ended
                                                    June 30,                          June 30,
                                         -------------------------------   -------------------------------
                                             2005              2004            2005              2004
                                         --------------   --------------   --------------   --------------
                                                             Restated                          Restated

<S>                                      <C>              <C>              <C>              <C>
REVENUE - SALES                          $        3,799   $       31,817   $        5,929   $       48,975

COSTS AND EXPENSES
    Cost of goods sold                              704           10,554            1,826           30,259
   Selling, general and administrative
      expenses                                  349,282          130,143          545,731          820,745
   Stock based compensation                         313                                                313
   Stock issued for marketing services           13,200                           119,700        1,943,361
   Stock issued for consulting services           5,547                             5,850           56,700
   Depreciation                                     280                               559               65
                                         --------------   --------------   --------------   --------------

             Total Costs and Expenses           369,326          140,697          673,979        2,851,130
                                         --------------   --------------   --------------   --------------

NET OPERATING LOSS                             (365,527)        (108,880)        (668,050)      (2,802,155)

OTHER EXPENSE
   Interest expense                                 (30)                              (30)
                                         --------------   --------------   --------------   --------------

             Total Other Expense                    (30)                              (30)
                                         --------------   --------------   --------------   --------------

NET LOSS                                 $     (365,557)  $     (108,880)  $     (668,080)  $   (2,802,155)
                                         ==============   ==============   ==============   ==============

NET LOSS PER SHARE OF COMMON
   STOCK                                 $         (.00)  $         (.00)  $         (.00)  $         (.01)
                                         ==============   ==============   ==============   ==============

WEIGHTED AVERAGE NUMBER
    OF COMMON  SHARES
    OUTSTANDING
                                            794,685,469      634,951,712      787,351,366      597,039,441
                                         ==============   ==============   ==============   ==============
</TABLE>


                 See accompanying notes to financial statements.
<PAGE>


              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)


<TABLE>
<CAPTION>
                                                                For the Six Months Ended
                                                                        June 30,
                                                             -------------------------------
                                                                   2005            2004
                                                             --------------   --------------
                                                                                 Restated
<S>                                                          <C>              <C>
CASH FLOWS FROM OPERATING ACTIVITIES
   Net loss                                                  $     (668,080)  $   (2,802,155)
   Stock issued for services                                        125,863        2,000,061
   Depreciation expense                                                 559               65
   Changes in assets and liabilities:
       Decrease (increase) in accounts receivable                       306           (1,152)
       (Increase) decrease in inventory                              (1,137)          55,341
      Increase in prepaid expenses                                  (13,200)
       Increase in other assets                                     168,960
      Decrease in accounts payable                                   (4,334)         (81,292)
      Increase in accrued expenses                                  132,463          354,977
      Increase in accrued expenses - stockholders                    97,966           83,410
                                                             --------------   --------------
        Net cash used in operating activities                      (329,594)        (221,785)

CASH FLOWS FROM INVESTING ACTIVITIES
   Cash paid for office equipment                                    (3,353)
   Cash paid for intangible assets                                   (5,579)
   Due from related parties                                          (4,500)          11,738
                                                             --------------   --------------
        Net cash (used in) provided by investing activities         (10,079)           8,385

CASH FLOWS FROM FINANCING ACTIVITIES
   Bank overdraft                                                     6,946
   Cash acquired in acquisition of subsidiary                           100
   Loans payable - stockholders' - net                               20,650         (119,500)
   Increase in deposits                                             345,000           10,000
   Proceeds from issuance of common stock                            56,500           60,000
                                                             --------------   --------------

        Net cash provided by financing activities                   429,096          (49,400)
                                                             --------------   --------------


        Net increase (decrease) in cash                              89,423         (262,800)

CASH AT BEGINNING OF PERIOD                                           1,045          265,858
                                                             --------------   --------------

CASH AT END OF PERIOD                                        $       90,468   $        3,058
                                                             ==============   ==============
</TABLE>


                 See accompanying notes to financial statements.

<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES.

                CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)


<TABLE>
<CAPTION>
                                                                      For the Six Months Ended
                                                                               June 30,
                                                                     -----------------------------

                                                                         2005           2004
                                                                     ------------  ---------------
                                                                                       Restated

<S>                                                                  <C>           <C>
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

   NON-CASH INVESTING AND FINANCING ACTIVITIES

      Issuance of common stock for services                          $    125,863  $    2,000,061

      Issuance of preferred stock in payment of loans payable
          to stockholders                                                  10,000

      Issuance of preferred stock in payment of accrued expenses
         to stockholders                                                   10,000

      Purchase of intangible assets for loan payable to stockholder        19,000

      Issuance of common stock in payment of loan payable
        to stockholder                                                                    500,000

      Assets acquired and liabilities assumed in acquisition of
      subsidiary:

        Cash acquired                                                                         100
        Goodwill                                                                            9,041
        Accrued expenses                                                                   (8,251)
        Loans payable - stockholders                                                         (890)
</TABLE>


                See accompanying notes to financial statements.

<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES.

                          NOTES TO FINANCIAL STATEMENTS
                                  JUNE 30, 2005


NOTE A - CONDENSED FINANCIAL STATEMENTS

In the opinion of the Company,  the accompanying  unaudited  condensed financial
statements  include  all  adjustments   (consisting  only  of  normal  recurring
accruals)  which are  necessary for a fair  presentation  of the results for the
periods  presented.  Certain  information  and  footnote  disclosure,   normally
included in the  financial  statements  prepared in  accordance  with  generally
accepted accounting principles,  have been condensed and omitted. The results of
operations  for the six months  ended June 30,  2005 are not  indicative  of the
results of  operations  for the year ended  December  31,  2005.  The  condensed
financial  statements should be read in conjunction with the Company's financial
statements  included in its annual Form 10 KSB for the year ended  December  31,
2004.

NOTE B - STOCK WARRANTS

At June 30, 2005,  the Company had  outstanding  warrants to purchase  7,000,000
shares of the Company's  common stock at a price of $.03 per share. The warrants
are exercisable and expire at various dates through 2007.

NOTE C - COMMITMENTS AND CONTINGENCIES

The Company has employment  agreements  with three  employees,  and a consulting
contract with a key consultant,  who are also  stockholders  of the Company.  At
June 30,  2005,  the Company has a total  liability  for  accrued  salaries  and
consulting  expense to stockholders of $852,800.  There could be certain payroll
tax liabilities  owed to the IRS on some of the payments for services to certain
consultants  that  were  paid in  prior  years,  pursuant  to  these  employment
agreements.

NOTE D - RELATED PARTIES STOCK AND ASSET TRANSACTIONS

On January 18, 2005,  the Company issued  30,000,000  shares of its common stock
under an S-8 filing with the Securities  and Exchange  Commission to consultants
at $0.00355 per share.  The aggregate  remuneration of $106,500 has been treated
as stock issued for marketing services and expensed in the current year.

In connection with a private  placement,  on January 24, 2005 the Company issued
10,000,000 shares of its common stock at $0.002 per share realizing $20,000.

On February 1, 2005, the Company issued  2,500,000 shares of its preferred stock
at $0.008 per share as payment of $20,000  against loans payable -  stockholders
and accrued expenses - stockholders.

On March 5, 2005,  Amazing  Nutritionals,  Inc.  ("Amazing") a subsidiary of the
Company, entered into an Agreement of Sale with Nature's Backyard, Inc., whereby
Amazing agreed to buy all  intellectual  property,  permits,  patents  (granted,
pending, or applied for), trademarks, processes, formulation, exact ingredients,
precise way of manufacturing,  and related items of the "Slim Cookie", a product
for weight loss and lowering cholesterol.  The purchase price is as follows: (a)
Payment of $1,000 and the issuance of 200,000  shares of common stock on signing
the  agreement,  (b) 300,000 shares of common stock upon signing and filing of a
provisional  patent  application  by the Company,  (c) 100,000  shares of common
stock upon the issuance of a patent by the U.S. Patent and Trademark Office, (d)
payment of $4,000 not more than 60 days from the execution of the Agreement, and
(e) payment of $15,000  within 270 days of the execution of the  Agreement.  The
Company has not made the required payment and is in default of the agreement.

On April 26, 2005, the Company issued 4,000,000 shares of its common stock under
an S-8 filing with the  Securities  and Exchange  Commission to  consultants  at
$0.00345 per share.  The  aggregate  remuneration  of $13,800 will be treated as
stock issued for marketing services and expensed in the current year.

<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES.

                    NOTES TO FINANCIAL STATEMENTS (CONTINUED)
                                  JUNE 30, 2005


NOTE D - RELATED PARTIES STOCK AND ASSET TRANSACTIONS (CONTINUED)

On April 26, 2005, the Company issued 5,000,000 shares of its common stock under
an S-8 filing with the Securities and Exchange  Commission at $0.00345 per share
as payment for accounts payable in the amount of $16,500.


NOTE E - GOING CONCERN

As reflected in the accompanying  financial statements,  the Company has current
liabilities  in excess of current  assets of  $3,782,630,  resulting in negative
working  capital.  Management  is presently  seeking to raise  permanent  equity
capital in the capital markets to eliminate negative working capital and provide
working  capital.  Failure to raise equity  capital or secure some other form of
long-term  debt  arrangement  will cause the  Company to  further  increase  its
negative  working  capital  deficit.  However,  there are no assurances that the
Company  will succeed in  obtaining  equity  financing or some form of long-term
debt instrument.


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS

BACKGROUND

Advanced Plant  Pharmaceuticals,  Inc. (the  "Company") was  incorporated in the
State of Delaware in 1986,  under the name Ventra  Management,  Inc. On July 20,
1994, we amended our Certificate of Incorporation to change our name to Advanced
Plant Pharmaceuticals, Inc.

DESCRIPTION OF BUSINESS

The Company  continues to focus on the research and  development  of plant based
dietary  supplements.  In July 1999, the Company  acquired  exclusive rights and
interests  to a  thirteen-step  process,  which  utilizes  virtually  all of the
nutrients found in plants to manufacture natural herbal dietary supplements. The
purchase  price for the thirteen  step process was  12,000,000  shares of common
stock of the Company.  The shares were issued on February 13, 2001. Further, the
Company is required to issue an additional 6,000,000 shares of common stock when
marketing of the product  commences.  The Company intends to use this process to
manufacture products that it hopes to distribute worldwide through various sales
distribution contracts.

On February 28, 2000, the Company entered into an Asset Purchase Agreement with
Dr. Bielory to purchase his various allergy and nasal formulations. This
agreement was approved by the Board of Directors on September 6, 2000. Dr.
Bielory was granted a five year option to purchase an aggregate of 18,000,000
shares of the Company's common stock at an exercise price of $180.00. Dr.
Bielroy exercised an option for 12,000,000 shares in the first quarter of 2001.

Sinusol, being the formulation purchased from Dr. Bielory, is a generalized base
solution for the development of an extensive line of specialty  products related
to allergy and sinus  conditions.  The  ingredients  include a mixture of gently
pH-balanced  essential  mineral oils that combat the various symptoms related to
allergies and sinus disorders, including congestions, irritated nasal mucosa and
bacterial and fungal  infections.  Specialized  advanced  formulations are being
reviewed for patent submission.

In addition to Sinusol,  the  Company is also  currently  marketing  its Lo-Chol
product.  Lo-Chol's  formula is  derived  from the  "whole  plant"  parts of six
selected  plants that work in concert to help tip your lipid  balance  (good and
bad   cholesterol)   towards  a  more  normal   level.   These  six  plants  are
synergistically combined using a proprietary "whole plant technology" (a special
pharmaceutical-grade   process)   that   delivers   virtually  all  the  natural
phyto-chemicals  and active  ingredients in the plants.  Unlike almost all other
herbal  supplements  on the  market,  Lo-Chol  does not  contain  any  extracts.
Instead,  it utilizes the entire part of a specific  plant that is processed and
standardized to deliver optimum potency and nutritional benefits.

RECENT DEVELOPMENTS

In January 2004,  the Company  acquired a 44% interest in Amazing  Nutritionals,
Inc., a development stage company,  whereby APPI sold Amazing all of the rights,
title,  patents,  trademarks,  processes  and related items of LHM123 which is a
natural  composition for the treatment of senile dementias in consideration  for
3,300,000 shares of Amazing's common stock.

In  December  2004,  the  Company   acquired  a  99%  interest  in  Mazal  Plant
Pharmaceuticals,  Inc. ("Mazal"), a development stage company, whereby APPI sold
Mazal all of its rights relating to or connected with developing,  manufacturing
and distributing of three of its products,  plant based compositions designed to
treat elevated  cholesterol,  leukemia and Alzheimer's  disease in consideration
for 7,000,000 shares of Mazal's common stock and a receivable of $50,000.

On June 6, 2005, the Company  consummated the  transactions  contemplated by the
Share Exchange  Agreement dated as of May 2005 (the "Share Exchange  Agreement")
by and  among the  Company,  Akid  Corporation  ("Akid")  and James B.  Wiegand.
Pursuant to the Share Exchange Agreement,  the Company sold its entire ownership
interest in 7,000,000  shares of the common stock of Mazal to Akid. In exchange,
Akid agreed to issue to the Company 20,000,000 shares (the "Exchange Shares") of
Akid's common stock.  Following the  consummation  of such share  exchange,  the
Company  holds a majority of the issued and  outstanding  common shares of Akid,
and Akid holds a majority of the issued and outstanding common shares of Mazal.

Akid issued to the Company 17,500,000 of the Exchange Shares at the closing, and
agreed to issue the remaining  2,500,000 of the Exchange  Shares upon increasing
its authorized common stock from 20,000,000 shares to 40,000,000 shares.

<PAGE>

RESULTS OF OPERATIONS

SIX MONTHS ENDED JUNE 30, 2005 COMPARED TO THE SIX MONTHS ENDED JUNE 30, 2004.

REVENUES

Revenues generated during the six months ended June 30, 2005, aggregated $5,929,
as compared to $48,975 for the six months ended June 30,  2004.  The decrease of
$43,046 in revenues  from the  comparable  period in the prior year is primarily
due to less purchases by our exclusive distributors.

COSTS OF GOODS SOLD

Cost of Goods Sold for the six months ended June 30, 2005,  aggregated  $673,979
as compared to $2,851,130  for the six months ended June 30, 2004.  The decrease
of  $2,177,151  for the six months  ended June 30,  2005 as  compared to the six
months  ended  June  30,  2004,  was  primarily  due to the  use of  product  in
connection with clinical trials.

OPERATING EXPENSES

Operating  Expenses  incurred for the six months ended June 30, 2005  aggregated
$673,979 as compared to $2,802,155 for the six months ended June 30, 2004, which
is a decrease of $2,128,176. This decrease was the result of a decrease in stock
issued for marketing services.

NET LOSS

The net loss was $688,050 for the six months ended June 30, 2005, as compared to
net loss of $2,802,155 for the six months ended June 30, 2004,  which represents
an decrease in the net loss of $2,114,105. The reason for the decreased net loss
is a result of the reasons described above.

THREE MONTHS ENDED JUNE 30, 2005 COMPARED TO THE THREE MONTHS ENDED JUNE 30,
2004.

REVENUES

Revenues  generated  during the three  months  ended June 30,  2005,  aggregated
$3,799,  as compared to $31,817 for the three months  ended June 30,  2004.  The
decrease of $28,018 in revenues from the comparable  period in the prior year is
primarily due to less purchases by our exclusive distributors.

COSTS OF GOODS SOLD

Cost of Goods Sold for the three months ended June 30, 2005,  aggregated $704 as
compared  to  $10,554  for the three  months  ended  June 30,  2004.  The $9,838
decrease  for the  three  months  ended  June 30,  2005,  was  primarily  due to
decreased sales.

OPERATING EXPENSES

Operating Expenses incurred for the three months ended June 30, 2005, aggregated
$369,326 as compared to $611,225 for three months ended June 30, 2004,  which is
a decrease  of  $241,899.  This  decrease  was the  result of a decrease  in the
payment of finders fees payable in connection with the sales of our products.

NET LOSS

The net loss was $365,557 for the three months ended June 30, 2005,  as compared
to net loss of $108,880 for the three months ended June 30, 2004. The reason for
the increased net loss is a result of the reasons described above.

LIQUIDITY AND CAPITAL RESOURCES

<PAGE>

At June 30, 2005, we had working  capital deficit of $3,782,630 as compared with
$3,288,393 at December 31, 2004. The increase in the working  capital deficit is
primarily the result of an increase in accrued expenses.

We  have   historically   sustained  our   operations  and  funded  our  capital
requirements  with the  funds  received  from the  sale of our  products,  loans
received from related parties and the sale of our securities. We will still need
additional  investments in order to continue operations.  Additional investments
are being sought,  but we cannot  guarantee  that we will be able to obtain such
investments.

Financing  transactions  may include the issuance of equity or debt  securities,
obtaining credit facilities, or other financing mechanisms. However, the trading
price of our common  stock and the  downturn in the U.S.  stock and debt markets
could make it more difficult to obtain financing  through the issuance of equity
or debt  securities.  Even if we are able to raise  the  funds  required,  it is
possible  that we could incur  unexpected  costs and  expenses,  fail to collect
significant amounts owed to us, or experience  unexpected cash requirements that
would force us to seek alternative  financing.  Further,  if we issue additional
equity or debt securities,  stockholders may experience  additional  dilution or
the new equity  securities may have rights,  preferences or privileges senior to
those of existing  holders of our common stock.  If additional  financing is not
available or is not available on acceptable  terms,  we will have to curtail our
operations again.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in conformity with accounting principles
generally  accepted in the United States  requires  management of the Company to
make  assumptions,  estimates and judgments that affect the amounts  reported in
the financial  statements,  including the notes thereto, and related disclosures
of commitments  and  contingencies,  if any. The Company  considers its critical
accounting policies to be those that require the more significant  judgments and
estimates in the preparation of the Company's  financial  statements,  including
the following:  valuation of inventories  and  intangible  assets,  valuation of
stock options and warrants,  and valuation of all accrued liabilities  including
payroll taxes and other contingent liabilities.  Management relies on historical
experience  and  on  other  assumptions  believed  to be  reasonable  under  the
circumstances in making its judgment and estimates.  Actual results could differ
materially from those estimates.

ITEM 3 - CONTROLS AND PROCEDURES

As of the end of the period covered by this report,  we conducted an evaluation,
under the supervision and with the  participation of our chief executive officer
and principal  financial  officer of our disclosure  controls and procedures (as
defined in Rule 13a-15(e) and Rule  15d-15(e) of the Exchange  Act).  Based upon
this evaluation,  our chief executive  officer and principal  financial  officer
concluded  that our  disclosure  controls and procedures are effective to ensure
that  information  required to be disclosed by us in the reports that we file or
submit under the Exchange Act is recorded,  processed,  summarized and reported,
within the time periods specified in the Commission's rules and forms. There was
no change in our internal  controls or in other  factors that could affect these
controls  during  our last  fiscal  year  that has  materially  affected,  or is
reasonably  likely to materially  affect,  our internal  control over  financial
reporting.

<PAGE>

                                     PART II

ITEM 1 - LEGAL PROCEEDINGS

From  time to  time,  the  Company  is a party  to  litigation  or  other  legal
proceedings  that  it  considers  to be a part  of the  ordinary  course  of its
business.  The Company is not involved currently in legal proceedings that could
reasonably  be  expected  to have a  material  adverse  effect on its  business,
prospects,  financial  condition  or results of  operations  except as set forth
below. We may become involved in material legal proceedings in the future.


ITEM 2 - CHANGES IN SECURITIES

On June 6, 2005, the Company  consummated the  transactions  contemplated by the
Share Exchange  Agreement dated as of May 2005 (the "Share Exchange  Agreement")
by and  among the  Company,  Akid  Corporation  ("Akid")  and James B.  Wiegand.
Pursuant to the Share Exchange Agreement,  the Company sold its entire ownership
interest in 7,000,000  shares of the common stock of Mazal to Akid. In exchange,
Akid agreed to issue to the Company 20,000,000 shares (the "Exchange Shares") of
Akid's common stock.  Following the  consummation  of such share  exchange,  the
Company  holds a majority of the issued and  outstanding  common shares of Akid,
and Akid holds a majority of the issued and outstanding common shares of Mazal.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 5 - OTHER INFORMATION

None

ITEM 6. - EXHIBITS

      31.1  Certification of the Chief Executive Officer and Principal Financial
            Officer of Advanced Plant Pharmaceuticals, Inc. pursuant to Section
            302 of the Sarbanes-Oxley Act of 2002.

      32.1  Certification of the Chief Executive Officer and Principal Financial
            Officer of Advanced Plant Pharmaceuticals, Inc. pursuant to Section
            906 of the Sarbanes-Oxley Act of 2002.

<PAGE>


                                   SIGNATURES

      In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                    ADVANCED PLANT PHARMACEUTICALS, INC.


                                     By:/s/ David Lieberman
                                        ----------------------------------------
                                        David Lieberman, Chief Executive Officer
                                        and Principal Financial Officer


Dated: August 22, 2005